Department of Diagnostic Radiology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan.
Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan.
Eur Radiol. 2023 Sep;33(9):6245-6255. doi: 10.1007/s00330-023-09627-8. Epub 2023 Apr 13.
To examine the clinical significance of the Vesical Imaging-Reporting and Data System (VI-RADS) in predicting outcome of multimodal treatment (MMT) in muscle-invasive bladder cancer (MIBC) patients.
We reviewed 78 pathologically proven MIBC patients who underwent MMT including transurethral resection and chemoradiotherapy, followed by partial or radical cystectomy. Treatment response was assessed through histologic evaluation of cystectomy specimens. Two radiologists categorized the index lesions of pretherapeutic MRI according to the 5-point VI-RADS score. The associations of VI-RADS score with the therapeutic effect of MMT were analyzed. The diagnostic performance of VI-RADS scores with a cut-off VI-RADS scores ≤ 2 or ≤ 3 for predicting pathologic complete response to MMT (MMT-CR) was evaluated.
MMT-CR was achieved in 2 (100%) of VI-RADS score 1 (n = 2), 16 (84%) of score 2 (n = 19), 12 (86%) of score 3 (n = 14), 7 (64%) of score 4 (n = 11), and 14 (44%) of score 5 (n = 32). VI-RADS score was inversely associated with the incidence of MMT-CR (p = 0.00049). The cut-off VI-RADS score ≤ 2 and ≤ 3 could predict the favorable therapeutic outcome of MMT with high specificity (0.89 with 95% confidence interval [CI]: 0.71-0.98 and 0.82 with 95% CI: 0.62-0.94, respectively) and high positive predictive value (0.86 with 95% CI: 0.64-0.97 and 0.86 with 95% CI: 0.70-0.95, respectively).
VI-RADS score may serve as an imaging marker in MIBC patients for predicting the therapeutic outcome of MMT.
Muscle-invasive bladder cancer patients with a lower Vesical Imaging-Reporting and Data System score can be a good candidate for bladder-sparing treatment incorporating multimodal treatment.
• Vesical Imaging-Reporting and Data System (VI-RADS) score was potentially valuable for classifying pathologic tumor response in patients with muscle-invasive bladder cancer. • The likelihood of achieving complete response of multimodal treatment (MMT) decreased with increasing VI-RADS score. • VI-RADS score could serve as an imaging marker that optimizes patient selection for MMT.
探讨膀胱影像学报告和数据系统(VI-RADS)在预测肌层浸润性膀胱癌(MIBC)患者多模态治疗(MMT)结局中的临床意义。
我们回顾了 78 例经病理证实的 MIBC 患者,这些患者接受了 MMT,包括经尿道切除术和放化疗,随后行部分或根治性膀胱切除术。通过对膀胱切除标本的组织学评估来评估治疗反应。两位放射科医生根据 5 分 VI-RADS 评分对术前 MRI 上的指数病变进行分类。分析 VI-RADS 评分与 MMT 治疗效果的相关性。评估截断值 VI-RADS 评分≤2 或≤3 预测 MMT 完全病理缓解(MMT-CR)的诊断性能。
VI-RADS 评分 1 分(n=2)、2 分(n=19)、3 分(n=14)、4 分(n=11)和 5 分(n=32)的 MMT-CR 分别为 2(100%)、16(84%)、12(86%)、7(64%)和 14(44%)。VI-RADS 评分与 MMT-CR 的发生率呈负相关(p=0.00049)。截断值 VI-RADS 评分≤2 和≤3 可预测 MMT 的良好治疗效果,具有较高的特异性(95%置信区间[CI]:0.71-0.98 和 0.82,95%CI:0.62-0.94)和高阳性预测值(95%CI:0.64-0.97 和 0.86,95%CI:0.70-0.95)。
VI-RADS 评分可作为 MIBC 患者的影像学标志物,用于预测 MMT 的治疗效果。
肌层浸润性膀胱癌患者的 Vesical Imaging-Reporting and Data System(VI-RADS)评分较低,可能是包含多模态治疗的膀胱保留治疗的良好候选者。
Vesical Imaging-Reporting and Data System(VI-RADS)评分对于分类肌层浸润性膀胱癌患者的病理肿瘤反应具有潜在价值。
多模态治疗(MMT)完全缓解的可能性随着 VI-RADS 评分的增加而降低。
VI-RADS 评分可作为一种影像学标志物,优化 MMT 患者的选择。